Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an investigational oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough.… From the company’s description.
In fiscal 2025, Trevi Therapeutics, Inc. reported a net loss of $42.76M. Operations used $42.09M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Trevi Therapeutics, Inc. does
In the company’s own words
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an investigational oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough. Haduvio acts as a kappa-opioid receptor agonist and mu-opioid receptor antagonist, and the company holds worldwide commercial rights. Its development programs address these three patient groups: the IPF program is advancing toward two planned Phase 3 trials, while Phase 2b trials are planned for non-IPF ILD and refractory chronic cough. The company’s potential customers include patients and healthcare providers, with planned U.S. commercialization targeting pulmonologists and other specialists if the drug receives regulatory approval. Trevi licenses nalbuphine rights from Keenova Therapeutics and relies on third parties to supply drug substance and manufacture tablets; it has no manufacturing facilities of its own. Its principal product brand is Haduvio, and it owns the Trevi trademark. Its website is www.trevitherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1563880
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Trevi Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Trevi Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Trevi Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Trevi Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Trevi Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”